Vale Biolabs
Startup
vale.bio/Schlieren, SwitzerlandAbout
Vale Biolabs is a Swiss biotechnology company combining human brain organoids with predictive AI to make drug development faster, more reliable and more human-relevant.
Today, most drugs entering clinical trials fail, often because traditional preclinical models cannot accurately predict how human biology will respond. Animal models and conventional cell cultures have important limitations in reproducing the complexity of human tissues and diseases, leading to costly failures and delays in bringing new treatments to patients.
At Vale Biolabs, we are building a new approach to preclinical drug testing. We grow human brain organoids, three-dimensional models of human tissue derived from stem cells, and use them to measure how drugs affect human biology. By combining advanced tissue engineering, automated experimentation and AI, we aim to predict drug efficacy, toxicity and mechanisms of action before compounds enter clinical trials.
Our technology is built around three core capabilities:
-
Accelerated and standardised organoid production. Our proprietary protocols allow us to generate functional human brain organoids in approximately 25 days and introduce ageing-associated features within two months. This enables us to study neurological diseases and drug responses on timelines compatible with pharmaceutical R&D.
-
Longitudinal, multimodal biological measurements. Through non-destructive imaging and electrophysiology, we repeatedly measure the same living tissue before, during and after drug exposure. Combined with molecular profiling, this allows us to capture how biological systems evolve in response to different compounds, rather than relying only on isolated endpoint measurements.
-
Predictive AI models trained on proprietary human biological data. We use these matched biological trajectories to develop AI models that learn the relationships between a compound, the initial biological state and the resulting response over time. Our goal is to predict how new compounds will affect human tissues and help pharmaceutical companies identify promising therapies earlier.
We are initially focused on neurological diseases, starting with Alzheimer's disease and expanding into Parkinson's disease and ALS. These are areas where existing preclinical models have struggled to translate into successful human treatments.
Our business model combines paid drug-testing studies for pharmaceutical and biotechnology companies with the development of disease-specific predictive AI models that can be licensed and adapted to customers' drug discovery programmes.
Based in Zurich, Vale Biolabs operates its own laboratory, integrating human stem cell biology, advanced imaging, electrophysiology, automation and machine learning. We work with pharmaceutical companies, biotechnology startups and leading research institutions to validate new therapeutic approaches using human-relevant experimental systems.
Our long-term vision is to make predictive human biology a standard part of drug development, reducing reliance on animal testing, improving the probability of clinical success and accelerating the development of treatments for patients.
Representatives
CEO & Founder
Vale Biolabs